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Abstract  
AIM: Multiple sclerosis (MS) is an inflammatory disease in which the fatty myelin sheaths around 
the axons of the brain and spinal cord are damaged. We Study the effect of Apitherapy in treatment 
of MS.  
MATERIAL AND METHODS: Fifty patients with MS, their ages ranged between 26-71 years, were 
subjected to complete clinical and neurological history and examination to confirm the diagnosis. All 
cases were under their regular treatment they were divided into two main groups, Group I received 
honey, pollen, royal jelly and propolis and were treated with apiacupuncture 3 times weekly, for 12 
months, in addition to their medical treatment, while group II remains on their ordinary medical 
treatment only. Apiacupuncture was done by bee stings for regulating the immune system.  
RESULTS: Results revealed that 4 patients showed some improvement regarding their defects in 
gait, bowel control, constipation and urination, while 12 cases, showed some mild improvement in 
their movement in bed, and better improvement in bed sores, sensation, and better motor power, 
only two cases of them were able to stand for few minutes with support.  
CONCLUSION: Although Apitherapy is not a curable therapy in MS, but it can be used to minimize 
the clinical symptoms of MS, and can be included among programs of MS therapy. 
  
 
 
 
 
Introduction 
Multiple sclerosis (MS) is an inflammatory 
disease in which the fatty myelin sheaths around the 
axons of the brain and spinal cord are damaged, 
leading to demyelination and scarring as well as a 
broad spectrum of signs and symptoms [1]. MS is an 
important problem both for people with the disease 
and for society. There is no cure, and alleviation of 
symptoms forms the cornerstone of care. Excessive 
fatigue that severely limits activity is experienced by at 
least two-thirds of the estimated 60,000 people with 
MS in the UK [2].  There is no known cure for multiple 
sclerosis. Treatments attempt to return function after 
an attack, prevent new attacks, and prevent disability 
[3]. MS medications can have adverse effects or be 
poorly tolerated, and many people pursue alternative 
treatments, despite the lack of supporting scientific 
study. The prognosis is difficult to predict; it depends 
on the subtype of the disease, the individual's disease 
characteristics, the initial symptoms and the degree of 
disability the person experiences as time advances [4, 
5]. The primary aims of therapy are returning function 
after an attack, preventing new attacks, and 
preventing disability [6].
 
 
      Apitherapy is the medical use of honey 
bee products. This can include the use of honey, 
pollen, bee bread, propolis, royal jelly, and apilarnil 
and bee venom.  Most claims of apitherapy have not 
been proved to the scientific standards of evidence-
based medicine and are anecdotal in nature. Bee 
venom therapy is an alternative form of healing. Bee 
venom therapy is the part of apitherapy which utilizes 
bee venom in the treatment of health conditions. 
However, bee venom is a complex mix of a variety of 
peptides and proteins, some of which have strong 
neurotoxic and immunogenic effects [7]. It has been 
used since ancient times to treat arthritis, rheumatism, 
back pain, skin diseases and in this modern age as an 
alternative therapy to treat autoimmune diseases, 
Lyme disease and chronic fatigue syndrome [8, 9].  
Some reports have shown beneficial effects of bee 
venom in postherpetic neuralgia [10], swine flu [11],
 
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
266                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
fibromyalgia and multiple sclerosis [12]. There is no 
standardized practice for the administration of bee 
venom.  
Thus this study aimed to evaluate the role of 
apitherapy (bee venom, honey, pollen, royal jelly and 
propolis) among cases with MS. 
 
Material and Methods 
This study was carried on Fifty patients known 
to be with MS. Diagnosis was confirmed by clinical 
examination and radiological studies [13, 14]. Twelve 
males and thirty eight females, their ages ranged 
between 26-71 years, with a mean of 38.7 ± 4.8, two, 
from those attending the outpatient clinic of Adult 
Neurology in National Research Centre, Dokki, 
Egypt,” over a period of three years from September 
2008 till April 2011.  All cases were subjected to 
complete clinical and neurological history and 
examination to confirm the diagnosis. There were 32 
cases with quadriparesis, (8 males and 24 female) 
and 18 cases with paraparesis (4 males and 14 
females). All cases were under their regular treatment 
either by corticosteroids, or interferon. These cases 
were divided into two main groups, each group 
consists of 25 cases (6 males and 19 females), Group 
I received honey, pollen, royal jelly and propolis and 
were treated with bee stings 3 times weekly, for 12 
months, started gradually by one sting then gradually 
increase up to 25 stings per session - “after sensitivity 
test was done” - in addition to their medical treatment, 
while group II remains on their ordinary medical 
treatment only.  Informed consent was signed by the 
patients and their caregivers to participate in the study 
including the following:   
Full general and neurological assessment, 
including full history and examination according to 
sheet prepared for the study, neurological 
examination on the beginning of the study to confirm 
the diagnosis then examination was repeated every 
two months to examine and detect the changes which 
may be happened for each case, and recorded in the 
form of scores starting from 0 for normal with no 
abnormal signs up to 5 for complete disability.  
Assessment parameters: General condition, 
depression, no energy fatigue, sleeping, heat 
tolerance, attention span, memory, rigidity, spasms 
and tremors were evaluated by scoring from 1 up 7, 
the condition scores starting from1 for normal with no 
abnormal signs up to 7 for bad by asking the patient 
and devalued during diagnosis.  
Apiacupuncture done by bee stings in the 
following points Du 13, 14, Li 11, S6, S9, points for 
cervical area and lumber area and vision points GB2 
and Li3 [15].  
 
Supplementation: All patients of both groups 
were ordered to receive 50 gm twice daily. For 100 g, 
(roughly 5 tbsp) is composed of Energy 1,272 kJ 
(304 kcal), Carbohydrates 82.4 g, Sugars 82.12 g, 
Dietary fiber 0.2 g, Fat 0 g, Protein 0.3 g, Water 17.10 
g, Riboflavin (vit. B2)  0.038 mg (3%), Niacin (vit. B3)  
0.121 mg (1%), Pantothenic acid (B5) 0.068 mg (1%), 
Vitamin B6 0.024 mg (2%), Folate (vit. B9) 2 μg (1%), 
Vitamin C 0.5 mg (1%), Calcium 6 mg (1%), Iron 0.42 
mg (3%), Magnesium 2 mg (1%), Phosphorus 4 mg 
(1%), Potassium 52 mg (1%), Sodium 4 mg (0%), Zinc 
0.22 mg (2%) [16].  
Laboratory studies: Three milliliters of fasting 
venous blood were drawn with a sterile plastic syringe 
from each case and control. One milliliter of the blood 
was gently placed in a dry clean plastic tube 
containing EDTA as a blood anticoagulant for the 
estimation of blood Hb concentration, using 
cyanomethe-hemoglobin method according to 
the procedure described by Betke and Savelsberg, 
1950 using Drabkin’s solution as a diluent [17]. The 
rest 2 ml. blood were gently placed in a dry clean 
plastic tube and left for 15 minutes to clot then 
centrifuged at 3500 rpm for separation of serum, 
which then kept in deep freeze at  -70ºC until analysis 
for estimation of  serum levels of calcium, zinc,  
copper, vitamin E and Folat. All these investigations 
were done at the beginning of the study and by the 
end of one year of supplementation and bee sting 
sessions.  
Statistical analysis: All data obtained were 
statistically analyzed using Microsoft Excel and SPSS 
11.5 for windows software package including, “t test, 
non-parametric Qui square, Mann witney and anova 
test” as (Steel and Torrie, 1980) [18]. 
 
Results 
In this study were included fifty patients 
diagnosed as MS, twelve males and thirty eight 
females, their ages ranged between 26-71 years, with 
a mean of 38.7 ± 4.8. Thirty two cases with 
quadriparesis, (8 males and 24 female) and 18 cases 
with paraparesis (4 males and 14 females). During the 
period of the study there was gradual assessment of 
signs and symptoms every 2 months for both groups 
of patients. This periodic assessment for both groups 
showed the improvement in the scores of signs 
recorded every two months as shown in Table (1 & 2). 
Results revealed that 4 patients out of 9 (44.4% of 
paraparesis cases), showed significant improvement 
regarding their defects in gait, bowel control, 
constipation and urination, while 12 cases out of 16 
cases (75% of quadriparesis cases), showed mild 
improvement in their movement in bed, and better 
improvement in bed sores, sensation, and better 
motor power, only two cases of them (12.5%) were 
able to stand for few minutes with support among 
patients of group I. Also Fig. 1 showed mild 
improvement. 
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Table 1: Scores of signs recorded every two months (1-12), for patients of group (I). 
Months 2 Months 4 Months 6 Months 8 Months 10 Months 12 Months 
General Condition 4.87 ± 0.440 4.57 ± 0.278 3.87 ± 0.398 3.71 ± 0.267 2.85 ± 0.243 2.37 ± 0.182 
Depression 3.50 ± 0.707 3.62 ± 0.625 3.37 ± 0.652 3.00 ± 0.534 2.62 ± 0.323 1.75 ± 0.25 
No Energy Fatigue 3.75 ± 0.647 3.37 ± 0.595 3.62 ± 0.893 4.25 ± 0.883 2.87 ± 0.665 2.75 ± 0.311 
Sleeping 3.75 ± 0.490 3.37 ± 0.679 2.50 ± 0.327 2.37 ± 0.323 1.75 ± 0.25 1.37 ± 0.182 
Heat tolerance 3.75 ± 0.725 3.37 ± 0.818 2.50 ± 0.590 2.37 ± 0.534 1.75 ± 0.462 1.37 ± 0.365 
Attention span 2.12 ± 0.479 2.00 ± 0.534 1.87 ± 0.398 1.50 ± 0.267 1.25 ± 0.163 1.25 ± 0.163 
Memory 2.12 ± 0.350 2.00 ± 0.462 1.75 ± 0.365 1.50 ± 0.188 1.62 ± 0.182 1.50 ± 0.188 
Rigidity 2.50 ± 0.50 2.50 ± 0.654 3.00 ± 0.731 2.25 ± 0.411 2.12 ± 0.479 1.62 ± 0.323 
Spasms 2.37 ± 0.595 1.87 ± 0.610 2.50 ± 0.462 1.75 ± 0.313 2.50 ± 0.707 1.87 ± 0.398 
Tremors 2.37 ± 0.32 2.50 ± 0.654 2.75 ± 0.674 2.25 ± 0.453 2.37 ± 0.679 2.01 ± 0.15 
Headaches 1.87 ± 0.639 2.62 ± 0.625 2.12 ± 0.398 1.62 ± 0.263 1.75 ± 0.313 1.37 ± 0.263 
Eye sight 2.50 ± 0.566 2.50 ± 0.566 2.25 ± 0.490 1.87 ± 0.440 1.87 ± 0.398 1.75 ± 0.313 
Speech 1.62 ± 0.263 1.62 ± 0.263 1.87 ± 0.295 1.50 ± 0.267 1.50 ± 0.267 1.37 ± 0.182 
Swallowing 1.37 ± 0.263 1.37 ± 0.182 1.37 ± 0.182 1.12 ± 0.125 1.25 ± 0.163 1.12 ± 0.125 
Numbness 2.62 ± 0.375 2.62 ± 0.375 2.25 ± 0.453 1.87 ± 0.295 1.62 ± 0.375 1.25 ± 0.163 
Balance 4.62 ± 0.800 3.87 ± 0.685 3.00 ± 0.843 2.50 ± 0.707 1.87 ± 0.692 1.50 ± 0.834 
Walking 4.37 ± 0.595 4.37 ± 0.595 4.50 ± 0.707 4.25 ± 0.75 3.87 ± 0.742 2.87 ± 0.639 
Hand coordination 2.62 ± 0.532 2.62 ± 0.460 1.87 ± 0.226 1.75 ± 0.25 1.50 ± 0.188 1.37 ± 0.182 
Writing 2.62 ± 0.679 2.87 ± 0.789 2.12 ± 0.548 1.87 ± 0.479 1.75 ± 0.365 1.62 ± 0.263 
Bladder & Bowel 4.12 ± 0.580 4.12 ± 0.580 3.50 ± 0.597 3.25 ± 0.526 2.37 ± 0.323 2.12 ± 0.226 
       
As shown in Table 3, the scores of symptoms 
recorded at start and the end of the investigation 
among patients for both groups. There was no 
statistical significant differences between group I and 
group II at the start of the study, regarding their 
general condition, depression, fatigue, sleeping heat 
tolerance, attention span, memory, rigidity, spasms 
and tremors, while by the end of the study there were 
significant improvement regarding general condition, 
depression sleeping, heat tolerance attention span, 
memory as well as rigidity and muscle spasms. 
Table 4 shows the comparison between the 
mean plasma and serum concentrations of 
micronutrients for both groups of MS at the start and 
end of the study. There were no statistical significant 
differences between group I and group II at the start of 
the study, regarding their mean plasma and serum 
concentrations of micronutrients for both groups of MS 
at the start and end of the study. 
 
Discussion 
MS affects the ability of nerve cells in the 
brain and spinal cord to communicate with each other 
effectively [3]. Theories include genetics or infections. 
Different environmental risk factors have also been 
found [19]. Life expectancy of people with MS is 5 to 
10 years lower than that of the unaffected population 
[1]. Several subtypes, or patterns of progression, have 
been described. Subtypes use the past course of the 
disease in an attempt to predict the future course. 
They are important not only for prognosis but also for 
therapeutic decisions [5]. Although there is no known 
cure for multiple sclerosis, several therapies have 
proven helpful.  
Bee sting therapy is increasingly used to treat 
patients with multiple sclerosis (MS) in the belief that it 
can stabilize or ameliorate the disease. However, 
there are no clinical studies to justify its use. 
Wesselius et al, 2005 found that there was no 
improvement of disability, fatigue, and quality of life 
[20]. Bee sting therapy was well tolerated, and there 
were no serious adverse events. They concluded that 
the treatment with bee venom in patients with 
relapsing multiple sclerosis did not reduce disease 
activity, disability, or fatigue and did not improve 
quality of life. 
The therapeutic benefits of honeybee venom 
have been known for a long time to relieve pain and to 
treat inflammatory diseases particularly for treatment 
of arthritic and rheumatic conditions in humans [21, 
22] and in animals [23-25]. Specific immunotherapy 
with bee venom can result in an almost complete 
protection against adverse (or allergic) reactions from 
stings in the great majority of cases [26]. 
 
 
Table 2: Scores of signs recorded every two months (1-12), for patients of group (II). 
Months 2 Months 4 Months 6 Months 8 Months 10 Months 12 Months 
General Condition 3.73 ± 0.5 3.49 ± 0.26 3.17 ± 0.23 3.01 ± 0.22 2.83 ± 0.13 2.8 ± 0.12 
Depression 3.62 ± 0.24 3.6 ± 0.35 3.29 ± 0.12 3.05 ± 0.72 2.76 ± 0.45 2.45 ± 0.33 
No Energy Fatigue 3.24 ± 0.6 3.25 ± 0.35 3.24 ± 0.38 3.28 ± 0.28 2.95 ± 0.85 2.85 ± 0.35 
Sleeping 3.4 ± 0.58 3.39 ± 0.46 3.07 ± 0.12 2.8 ± 0.62 2.35 ± 0.25 2.07 ± 0.12 
Heat tolerance 3.5 ± 0.75 3.39 ± 0.16 3.06 ± 0.590 2.73 ± 0.63 2.5 ± 0.42 2.37 ± 0.365 
Attention span 2.1 ± 0.45 2.06 ± 0.32 1.93 ± 0.66 1.67 ± 0.21 1.53 ± 0.62 1.38 ± 0.22 
Memory 2.3 ± 0.35 2.13 ± 0.27 2.05 ± 0.05 1.92 ± 0.27 1.82 ± 0.15 1.72 ± 0.13 
Rigidity 2.48 ± 0.52 2.39 ± 0.52 2.17 ± 0.33 2.06 ± 0.18 1.92 ± 0.72 1.84 ± 0.23 
Spasms 2.4 ± 0.58 2.26 ± 0.19 2.19 ± 0.25 2.03 ± 0.18 1.89 ± 0.09 1.74 ± 0.398 
Tremors 2.36 ± 0.43 2.3 ± 0.52 2.28 ± 0.45 2.2 ± 0.32 2.17 ± 0.66 2.12 ± 0.718 
Headaches 1.86 ± 0.19 1.72 ± 0.23 1.66 ± 0.32 1.59 ± 0.28 1.49 ± 0.19 1.42 ± 0.23 
Eye sight 2.48 ± 0.36 2.39 ± 0.34 2.31 ± 0.09 2.27 ± 0.62 2.13 ± 0.18 2.01 ± 0.13 
Speech 1.59 ± 0.63 1.55 ± 0.17 1.49 ± 0.24 1.44 ± 0.15 1.4 ± 0.28 1.37 ± 0.08 
Swallowing 1.45 ± 0.21 1.41 ± 0.22 1.38 ± 0.42 1.32 ± 0.19 1.29 ± 0.33 1.26 +0.25 
Numbness 2.5 ± 0.5 2.42 ± 0.34 2.23 ± 0.66 2.07 ± 0.35 1.91 ± 0.07 1.72 ± 0.12 
Balance 3.49 ± 0.26 3.37 ± 0.63 3.02 ± 0.42 2.71 ± 0.17 2.47 ± 0.32 2.05 ± 0.47 
Walking 3.3 ± 0.62 3.27 ± 0.25 3.14 ± 0.45 3.07 ± 0.37 2.96 ± 0.52 2.87 ± 0.639 
Hand coordination 2.7 ± 0.28 2.6 ± 0.34 2.47 ± 0.56 2.35 ± 0.77 2.19 ± 0.28 2.04 ± 0.12 
Writing 2.65 ± 0.25 2.57 ± 0.09 2.42 ± 0.52 2.31 ± 0.08 2.18 ± 0.33 2.02 ± 0.26 
Bladder & Bowel 3.09 ± 0.35 2.96 ± 0.65 2.83 ± 0.42 2.79 ± 0.67 2.69 ± 0.44 2.63 ± 0.16 
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In our study we found that there is a 
statistically significant improvement regarding their 
immunity and the improvement in their health and 
general conditions and this is explained by [27, 28], 
that Bee stings cause hemoconcentration which might 
be related to the marked edema induced by the 
venom. Following bee stings there is an increase in 
various cytokines like interleukin (IL)-1β, IL-6, tumor 
necrosis factor-α, etc. In a mouse model using the 
subcutaneous route, rapid increases in serum alanine 
aminotransferase and aspartate aminotransferase 
transaminases, creatinine, urea nitrogen, uric acid, 
sodium and chloride electrolytes, and creatine kinase 
were recorded [27, 28].
 
 
 
Table 3: Comparison between patients of group I & group II regarding the signs at the start and end of the study. 
 
Clinical signs 
Mean  ±  SE of signs at the start of the  study 
P - value 
Mean  ±  SE of signs at the end of the  
study 
P - value 
Group I 
(n= 25) 
Group II 
(n= 25) 
Group I 
(n= 25) 
Group II 
(n= 25) 
General Condition 4.87 ± 0.440 3.73 ± 0.5 0.06 2.37 ± 0.182 2.8 ± 0.12 0.05 
Depression 3.5 ± 0.707 3.62 ± 0.24 0.1 1.75 ± 0.25 2.45 ± 0.33 0.004 
No Energy Fatigue 3.75 ± 0.647 3.24 ± 0.6 0.05 2.75 ± 0.311 2.85 ± 0.35 0.04 
Sleeping 3.75 ± 0.49 3.4 ± 0.58 0.07 1.37 ± 0.182 2.07 ± 0.12 0.003 
Heat tolerance 3.75 ± 0.725 3.5 ± 0.75 0.05 1.37 ± 0.365 2.37 ± 0.365 0.005 
Attention span 2.12 ± 0.479 2.1 ± 0.45 0.2 1.25 ± 0.163 1.38 ± 0.22 0.04 
Memory 2.12 ± 0.350 2.3 ± 0.35 0.1 1.50 ± 0.188 1.72 ± 0.13 0.02 
Rigidity 2.5 ± 0.5 2.48 ± 0.52 0.2 1.62 ± 0.323 1.84 ± 0.23 0.05 
Spasms 2.37 ± 0.595 2.4 ± 0.58 0.3 1.87 ± 0.398 1.74 ± 0.398 0.05 
Tremors 2.37 ± 0.32 2.36 ± 0.43 0.5 2.01 ± 0.15 2.12 ± 0.718 0.1 
 Headaches 1.87  ± 0.639 1.86  ± 0.19 0.02 1.37  ± 0.263 1.42  ± 0.23 0.02 
Eye sight 2.50  ± 0.566 2.48  ± 0.36 0.005 1.75  ± 0.313 2.01  ± 0.13 0.005 
Speech 1.62  ± 0.263 1.59  ± 0.63 0.04 1.37  ± 0.182 1.37  ± 0.08 0.04 
Swallowing 1.37  ± 0.263 1.45  ± 0.21 0.05 1.12 +0.125 1.26 +0.25 0.05 
Numbness 2.62  ± 0.375 2.5  ± 0.5 0.05 1.25  ± 0.163 1.72  ± 0.12 0.05 
Balance 4.62  ± 0.800 3.49  ± 0.26 0.005 1.50  ± 0.834 2.05  ± 0.47 0.005 
Walking 4.37  ± 0.595 3.3  ± 0.62 0.04 2.87  ± 0.639 2.87  ± 0.639 0.04 
Hand coordination 2.62  ± 0.532 2.7  ± 0.28 0.005 1.37  ± 0.182 2.04  ± 0.12 0.02 
Writing 2.62  ± 0.679 2.65  ± 0.25 0.04 1.62  ± 0.263 2.02  ± 0.26 0.005 
Bladder & Bowel 4.12  ± 0.580 3.09  ± 0.35 0.05 2.12  ± 0.226 2.63  ± 0.16 0.04 
 
 
According to Janik et al, 2007 [10], course of 
treatment starts with testing the patient for allergy, 
which is known to occur in 1% of the general 
population. Bee venom is administered in the form of 
a direct bee sting or else by injection of a venom 
extract, the treatment is usually given twice a week, 
this is agreed with our study we tested the patients for 
allergy, and we used the direct bee sting twice weekly 
for 6 months for each patients.  
Bee venom acupuncture (BVA), as a kind of 
herbal acupuncture, exerts not only pharmacological 
actions from the bioactive compounds isolated from 
bee venom but also a mechanical function from 
acupuncture stimulation. BVA is growing in popularity, 
especially in Korea, and is used primarily for pain 
relief in many kinds of diseases [29].  
We used Bee venom therapy for patients with 
MS and this is agreed with Park et al., 2010 and 
Prado et al., 2010, they stated that Bee venom 
therapy is used by people with many different 
autoimmune disorders, including MS, rheumatoid 
arthritis, lupus and scleroderma. It is also used for a 
number of other diseases and conditions, including 
depression, skin conditions, menstrual cramps and 
varicose veins [27, 28].  It is claimed that bee venom 
therapy works with the patient's own body to reduce 
inflammation. The theory is that because the stings 
produce inflammation, the body mounts an anti-
inflammatory response. Presumably, this would then 
work to reduce inflammation where the myelin is being 
attacked by the immune system in a person with MS 
[27, 28]  
The location of the sting is important, with the 
sting acting as a sort of acupuncture in combination 
with the effects of the venom, while others report the 
location is not important. The number of stings also 
varies widely from a few to hundreds and they may be 
administered either by live bees or by injection. This 
treatment can cause pain, and even result in death if 
the subject has an allergy to bee venom, which can 
produce anaphylactic shock [20]. For honeybee 
venom subcutaneous immunotherapy 100 or 200 μg 
doses are considered effective.   
 
Table 4: Shows the comparison between the mean plasma and serum concentrations of micronutrients for both groups of MS at 
the start and end of the study. 
 
Nutrient Level 
Mean  ±  SE of plasma concentration among 
cases  at the start of the study 
P – value 
Mean  ±  SE of plasma concentration among 
cases  at the end of the study 
P - value 
Group I 
(n= 25) 
Group II 
(n= 25) 
Group I 
(n= 25) 
Group II 
(n= 25) 
Iron (µmol/l) 9.26  ±  3.2 9.14  ±  1.7 0.1 12.1  ±  0.9 10.6  ±  1.4 0.02 
Calcium ( mg/dl ) 1.83  ±  0.04 1.85  ±  0.02 0.12 2.09  ±  0.02 1.9  ±  0.04 0.005 
Zinc (µg/dl) 14.2  ±  1.3 13.9  ±  1.5 0.06 16.7  ±  2.03 14.1  ±  2.02 0.04 
Copper (µg/dl) 17.9  ±  3.4 18.1  ±  2.6 0.07 20.05  ±  0.6 18.9  ±  1.9 0.05 
Vit. E (mg/dl) 20.8 ±  3.5 21.1 ±  2.8 0.1 23.9  ±  2.6 22.3 ±  2.4 0.05 
Folate (nmcl/l) 32.2  ±  2.7 31.9  ±  7.8 0.3 49.6  ±  6.4 34.6  ±  5.9 0.005 
Magnesium ( mmol/l ) 0.64  ±  0.05 0.65  ±  0.02 0.05 1.04   ±  0.03 0.98  ±  0.04 0.04 
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The median lethal dose (LD50) for honeybee 
venom has been reported in a number of reports [30, 
31] as 2.8 mg venom/kg body weight for intravenous 
and 3.8 mg venom/kg body weight for intraperitonealy 
delivery in mice. 
A 2004 randomized crossover study was 
conducted in the Netherlands among 24 people with 
either relapsing-remitting MS or secondary-
progressive MS. While the treatment was well- 
tolerated, no beneficial effects were seen on the MRIs 
or clinically among these patients [3, 5]. In our study 
there was a statistical significant improvement 
regarding the clinical findings while results of MRIs  
done for follow up for our patients showed that there is 
no more changes in the demyelinating lesions which 
means that demyelination shows no progression.  
 
 
Fig. 1 showed CT at the start and by the end of the study. 
 
Despite a lack of scientific evidence, bee 
venom therapy has been reported by people with MS 
to increase stability, as well as reduce fatigue and 
spasticity. More than 1,300 people with MS have sent 
testimonials to the American Apitherapy Society in 
support of the therapy [3], this is agreed by our study 
as patients under bee venom therapy showed marked 
improvement in stature, stability, and spasticity, While 
our study is disagreed with  Castro et al, 2005 [7] they  
found that there were no definite conclusions 
regarding efficacy and therefore there was little 
evidence to support the use of honeybee venom in the 
treatment of MS. Larger and more carefully conducted 
multicenter studies will be required to establish 
efficacy. 
In conclusion, although Apitherapy is not a 
curable therapy in MS, but it can be used to minimize 
the clinical symptoms of MS, and can be included 
among programs of MS therapy. 
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